{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:05:20Z","timestamp":1780761920812,"version":"3.54.1"},"reference-count":118,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.lpm.2023.104169","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T17:07:04Z","timestamp":1690477624000},"page":"104169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cystic fibrosis"],"prefix":"10.1016","volume":"52","author":[{"given":"Isabelle","family":"Fajac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0001","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0002","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chest.2022.07.004","article-title":"The changing epidemiology of cystic fibrosis: the implications for adult care","volume":"163","author":"Burgel","year":"2023","journal-title":"Chest"},{"issue":"9719","key":"10.1016\/j.lpm.2023.104169_bib0003","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(09)62161-9","article-title":"Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis","volume":"375","author":"McCormick","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2023.104169_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02288-2020","article-title":"Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry Cohort study","author":"McKone","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01487-2021","article-title":"Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries","volume":"58","author":"Martin","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0006","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/thorax-2022-219086","article-title":"Beyond borders: cystic fibrosis survival between Australia, Canada, France and New Zealand","volume":"78","author":"Coriati","year":"2023","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.lpm.2023.104169_bib0007","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","article-title":"The prevalence of cystic fibrosis in the European Union","volume":"7","author":"Farrell","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.lpm.2023.104169_bib0008","article-title":"Contemporary cystic fibrosis incidence rates in Canada and the United States","author":"Stephenson","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.lpm.2023.104169_bib0009","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1172-7-14","article-title":"Evidence for decline in the incidence of cystic fibrosis: a 35-year observational study in Brittany, France","volume":"7","author":"Scotet","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"23","key":"10.1016\/j.lpm.2023.104169_bib0010","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1001\/jama.2009.1758","article-title":"Association between carrier screening and incidence of cystic fibrosis","volume":"302","author":"Castellani","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2023.104169_bib0011","unstructured":"Orenti A., Zolin A., Jung A., van Rens J., et al. ECFSPR annual report 2020, www.ecfs.eu\/ecfspr. 2022."},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0012","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1183\/09031936.00196314","article-title":"Future trends in cystic fibrosis demography in 34 European countries","volume":"46","author":"Burgel","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Saint-Criq","year":"2017","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0014","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01307-2022","article-title":"Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond","volume":"61","author":"Mall","year":"2023","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2023.104169_bib0015","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jcf.2022.09.010","article-title":"Structure basis of CFTR folding, function and pharmacology","volume":"22","author":"Hwang","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"4922","key":"10.1016\/j.lpm.2023.104169_bib0016","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"issue":"4922","key":"10.1016\/j.lpm.2023.104169_bib0017","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.lpm.2023.104169_bib0018","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009480","article-title":"Assessing the disease-liability of mutations in CFTR","volume":"2","author":"Ferec","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"10.1016\/j.lpm.2023.104169_bib0019","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","article-title":"Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice","volume":"7","author":"Castellani","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/genes12040562","article-title":"Cystic fibrosis lung disease modifiers and their relevance in the new era of precision medicine","volume":"12","author":"Sepahzad","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.lpm.2023.104169_bib0023","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181s","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2023.104169_bib0024","article-title":"Genetic diagnosis in practice: from cystic fibrosis to CFTR-related disorders","volume":"27","author":"Pagin","year":"2020","journal-title":"Arch Pediatr"},{"issue":"5","key":"10.1016\/j.lpm.2023.104169_bib0025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1542\/peds.12.5.549","article-title":"Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease","volume":"12","author":"Di Sant'Agnese","year":"1953","journal-title":"Pediatrics"},{"key":"10.1016\/j.lpm.2023.104169_bib0026","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1152\/physiol.00041.2006","article-title":"Cystic fibrosis: lessons from the sweat gland","volume":"22","author":"Quinton","year":"2007","journal-title":"Physiology"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0027","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jpeds.2007.03.002","article-title":"Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines","volume":"151","author":"LeGrys","year":"2007","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/genes11060619","article-title":"Molecular diagnosis and genetic counseling of cystic fibrosis and related disorders: new challenges","volume":"11","author":"Bienvenu","year":"2020","journal-title":"Genes"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0029","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jcf.2022.09.011","article-title":"ECFS standards of care on CFTR-related disorders: updated diagnostic criteria","volume":"21","author":"Castellani","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0030","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jcf.2022.09.005","article-title":"ECFS standards of care on CFTR-related disorders: diagnostic criteria of CFTR dysfunction","volume":"21","author":"Sermet-Gaudelus","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.lpm.2023.104169_bib0031","first-page":"491","article-title":"[Newborn screening for cystic fibrosis in France]","volume":"37","author":"Munck","year":"2021","journal-title":"Med Sci"},{"issue":"8","key":"10.1016\/j.lpm.2023.104169_bib0032","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-2600(16)00053-9","article-title":"Newborn screening for cystic fibrosis","volume":"4","author":"Castellani","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2023.104169_bib0033","article-title":"European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance","author":"Munck","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.lpm.2023.104169_bib0034","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcf.2020.11.006","article-title":"Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome\/cystic fibrosis screen positive, inconclusive diagnosis (CRMS\/CFSPID)","volume":"20","author":"Barben","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/ejhg.2015.99","article-title":"The improvement of the best practice guidelines for preimplantation genetic diagnosis of cystic fibrosis: toward an international consensus","volume":"24","author":"Girardet","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0036","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMe020070","article-title":"What is cystic fibrosis?","volume":"347","author":"Knowles","year":"2002","journal-title":"N Engl J Med"},{"issue":"9636","key":"10.1016\/j.lpm.2023.104169_bib0037","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(08)61162-9","article-title":"Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis","volume":"372","author":"Quinton","year":"2008","journal-title":"Lancet"},{"issue":"7405","key":"10.1016\/j.lpm.2023.104169_bib0038","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11130","article-title":"Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung","volume":"487","author":"Pezzulo","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0039","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0040","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1183\/09031936.00228013","article-title":"CFTR: cystic fibrosis and beyond","volume":"44","author":"Mall","year":"2014","journal-title":"Eur Respir J"},{"issue":"486","key":"10.1016\/j.lpm.2023.104169_bib0041","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav3488","article-title":"Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis","volume":"11","author":"Esther","year":"2019","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.lpm.2023.104169_bib0042","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122695","article-title":"Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR","volume":"3","author":"Donaldson","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.lpm.2023.104169_bib0043","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jcf.2015.09.002","article-title":"Causes of death in French cystic fibrosis patients: the need for improvement in transplantation referral strategies!","volume":"15","author":"Martin","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0044","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17476348.2016.1177460","article-title":"Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches","volume":"10","author":"Lund-Palau","year":"2016","journal-title":"Expert Rev Respir Med"},{"issue":"9","key":"10.1016\/j.lpm.2023.104169_bib0045","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104169_bib0046","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1164\/rccm.201002-0157OC","article-title":"Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax","volume":"182","author":"Flume","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.lpm.2023.104169_bib0047","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1164\/rccm.201507-1281OC","article-title":"Morphometric analysis of explant lungs in cystic fibrosis","volume":"193","author":"Boon","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0048","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines","volume":"18","author":"Ramos","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"10.1016\/j.lpm.2023.104169_bib0049","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0050","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cgh.2012.11.006","article-title":"Gastrointestinal complications of cystic fibrosis","volume":"11","author":"Gelfond","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.lpm.2023.104169_bib0051","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jcf.2017.07.002","article-title":"Cystic fibrosis-related cirrhosis","volume":"16","author":"Leung","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.lpm.2023.104169_bib0052","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s10620-015-3546-7","article-title":"Gastrointestinal manifestations of cystic fibrosis","volume":"60","author":"Kelly","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0053","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2017.12.012","article-title":"Cystic fibrosis colorectal cancer screening consensus recommendations","volume":"154","author":"Hadjiliadis","year":"2018","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1016\/j.lpm.2023.104169_bib0054","article-title":"Cystic fibrosis related diabetes: medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0055","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ccm.2022.06.013","article-title":"Endocrine complications of cystic fibrosis","volume":"43","author":"Kelly","year":"2022","journal-title":"Clin Chest Med"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101444","article-title":"Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis","volume":"49","author":"Weiss","year":"2023","journal-title":"Diabetes Metab"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0057","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/lio2.401","article-title":"Chronic rhinosinusitis in patients with cystic fibrosis-current management and new treatments","volume":"5","author":"BJ","year":"2020","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0058","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00467-013-2712-4","article-title":"Electrolyte abnormalities in cystic fibrosis: systematic review of the literature","volume":"29","author":"Scurati-Manzoni","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"10.1016\/j.lpm.2023.104169_bib0059","first-page":"647","article-title":"[Severe dehydration and August 2003 heat wave in a cohort of adults with cystic fibrosis]","volume":"34","author":"Desmazes-Dufeu","year":"2005","journal-title":"Presse Med"},{"issue":"2","key":"10.1016\/j.lpm.2023.104169_bib0060","first-page":"119","article-title":"Cystic fibrosis as a cause of infertility","volume":"4","author":"Jarzabek","year":"2004","journal-title":"Reprod Biol"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0061","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.chest.2021.07.024","article-title":"Fertility and pregnancy in cystic fibrosis","volume":"160","author":"Shteinberg","year":"2021","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0062","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jcf.2021.07.019","article-title":"Pregnancy in cystic fibrosis: review of the literature and expert recommendations","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0063","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.med.0000436191.87727.ec","article-title":"Cystic fibrosis-related bone disease: insights into a growing problem","volume":"20","author":"Stalvey","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"12","key":"10.1016\/j.lpm.2023.104169_bib0064","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","article-title":"International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety","volume":"71","author":"Quittner","year":"2016","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.lpm.2023.104169_bib0066","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1111\/bcp.15434","article-title":"Antibiotic hypersensitivity in cystic fibrosis - low frequency of anaphylaxis over 16\u2009000 courses","volume":"88","author":"Kowalik","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0067","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcf.2018.08.014","article-title":"Defining antimicrobial resistance in cystic fibrosis","volume":"17","author":"Kidd","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.lpm.2023.104169_bib0068","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0022-3476(64)80290-0","article-title":"A therapeutic regimen for patients with cystic fibrosis","volume":"65","author":"Matthews","year":"1964","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.lpm.2023.104169_bib0069","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17476348.2019.1552832","article-title":"Acute and chronic non-pulmonary complications in adults with cystic fibrosis","volume":"13","author":"Regard","year":"2019","journal-title":"Expert Rev Respir Med"},{"issue":"10","key":"10.1016\/j.lpm.2023.104169_bib0071","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines - chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0072","first-page":"522","article-title":"Cystic fibrosis pulmonary guidelines: airway clearance therapies","volume":"54","author":"Flume","year":"2009","journal-title":"Respir Care"},{"issue":"6617","key":"10.1016\/j.lpm.2023.104169_bib0073","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"issue":"44","key":"10.1016\/j.lpm.2023.104169_bib0074","doi-asserted-by":"crossref","first-page":"36639","DOI":"10.1074\/jbc.M112.393637","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner","volume":"287","author":"Eckford","year":"2012","journal-title":"J Biol Chem"},{"issue":"46","key":"10.1016\/j.lpm.2023.104169_bib0075","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.lpm.2023.104169_bib0076","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.lpm.2023.104169_bib0077","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lpm.2023.104169_bib0078","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1164\/rccm.202112-2852LE","article-title":"Change in lung function after initiation of elexacaftor-tezacaftor-ivacaftor: do not forget anatomy!","volume":"205","author":"Martin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.lpm.2023.104169_bib0079","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0081","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0082","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.lpm.2023.104169_bib0083","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1164\/rccm.202109-2121LE","article-title":"Major decrease in lung transplantation for patients with cystic fibrosis in France","volume":"205","author":"Martin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0084","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01402-2022","article-title":"Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor-tezacaftor-ivacaftor, Germany, 2012-2021","volume":"61","author":"Ringshausen","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0085","doi-asserted-by":"crossref","first-page":"e14404","DOI":"10.1111\/petr.14404","article-title":"Changing racial and ethnic differences for lung transplantation in cystic fibrosis","volume":"27","author":"Hayes","year":"2023","journal-title":"Pediatr Transplant"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0086","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jcf.2021.12.002","article-title":"Outcomes following lung re-transplantation in patients with cystic fibrosis","volume":"21","author":"Chan","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.lpm.2023.104169_bib0087","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0088","doi-asserted-by":"crossref","first-page":"17834","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0089","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"10.1016\/j.lpm.2023.104169_bib0090","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-tezacaftor- ivacaftor improves sinonasal outcomes in cystic fibrosis","volume":"21","author":"Stapleton","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.lpm.2023.104169_bib0091","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0092","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccm.2022.06.015","article-title":"Family planning and reproductive health in cystic fibrosis","volume":"43","author":"Meiss","year":"2022","journal-title":"Clin Chest Med"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2016.09.003","article-title":"Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation","volume":"15","author":"Sermet-Gaudelus","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"10.1016\/j.lpm.2023.104169_bib0094","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jcf.2019.08.017","article-title":"Cystic fibrosis bone disease treatment: current knowledge and future directions","volume":"18","author":"Putman","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2017.05.008","article-title":"Worsening anxiety and depression after initiation of lumacaftor\/ivacaftor combination therapy in adolescent females with cystic fibrosis","volume":"16","author":"McKinzie","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0096","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.lpm.2023.104169_bib0097","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jcpt.13329","article-title":"A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators","volume":"46","author":"Gavioli","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.lpm.2023.104169_bib0098","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0099","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2023.104169_bib0100","unstructured":"Food and Drug Administration. Trikafta 2021 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf."},{"key":"10.1016\/j.lpm.2023.104169_bib0101","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(22)00377-0","article-title":"Treatment effects of elexacaftor\/tezacaftor\/ivacaftor in people with CF carrying non-F508del mutations","author":"Livnat","year":"2022","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.lpm.2023.104169_bib0102","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02437-2022","article-title":"The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2023.104169_bib0103","article-title":"New approaches to genetic therapies for cystic fibrosis","volume":"19","author":"Christopher Boyd","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"17\u201318","key":"10.1016\/j.lpm.2023.104169_bib0104","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1089\/hum.2020.166","article-title":"New directions in pulmonary gene therapy","volume":"31","author":"Vu","year":"2020","journal-title":"Hum Gene Ther"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0105","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.lpm.2023.104169_bib0106","doi-asserted-by":"crossref","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat Rev Mater"},{"issue":"4","key":"10.1016\/j.lpm.2023.104169_bib0107","doi-asserted-by":"crossref","first-page":"e1641","DOI":"10.1002\/wrna.1641","article-title":"Therapeutic promise of engineered nonsense suppressor tRNAs","volume":"12","author":"Porter","year":"2021","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"13","key":"10.1016\/j.lpm.2023.104169_bib0108","first-page":"7454","article-title":"Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells","volume":"48","author":"Michaels","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.lpm.2023.104169_bib0109","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2023.104169_bib0110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fphar.2019.00074","article-title":"Challenges facing airway epithelial cell-based therapy for cystic fibrosis","volume":"10","author":"Berical","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lpm.2023.104169_bib0111","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2 through 5 years with cystic fibrosis and at least one F508del allele","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2023.104169_bib0112","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00014-2021","article-title":"Impact of a high emergency lung transplantation programme for cystic fibrosis in France: insight from a comparison with Canada","volume":"59","author":"Coriati","year":"2022","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2023.104169_bib0113","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.lpm.2023.104169_bib0114","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1126697","article-title":"Systems prediction of chronic lung allograft dysfunction: results and perspectives from the Cohort of Lung Transplantation and Systems prediction of Chronic Lung Allograft Dysfunction cohorts","volume":"10","author":"Pison","year":"2023","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.lpm.2023.104169_bib0115","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jcf.2022.08.014","article-title":"Availability of CFTR modulators in countries of Eastern Europe: the reality in 2022","volume":"21","author":"Drevinek","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.lpm.2023.104169_bib0116","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lpm.2023.104169_bib0117","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del Alleles","author":"Graeber","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2023.104169_bib0118","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density but lung infections generally persist","author":"Nichols","year":"2023","journal-title":"J Clin Invest"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498223000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498223000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T07:39:04Z","timestamp":1698478744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498223000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0755498223000064"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2023.104169","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2023.104169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104169"}}